Home » Authors » Kim Coghill

Kim Coghill

Articles

ARTICLES

Amgen Gets No Aranesp Relief In Proposed Reimbursement Rule

Aug. 8, 2003

Amgen Gets No Aranesp Relief In Proposed Reimbursement Rule

Aug. 8, 2003

Cellegy Gets Cellegesic Back On Track With New Phase III

Aug. 7, 2003

Cellegy Gets Cellegesic Back On Track With New Phase III

Aug. 7, 2003

ISTA Increases Vitrase Filings, Submits Spreading Agent NDA

Aug. 6, 2003

Actelion, Celltech Receive FDA Approval For Zavesca

Aug. 6, 2003

ISTA Increases Vitrase Filings, Submits Spreading Agent NDA

Aug. 6, 2003

Actelion, Celltech Receive FDA Approval For Zavesca

Aug. 6, 2003

CV Therapeutics, FDA Agree To Cancel Ranexa Panel Meeting

Aug. 5, 2003

ActivBiotics Raises $26.4M In Series B Round For Trials

Aug. 5, 2003

View All Articles by Kim Coghill

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...